Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? - Reply

被引：1
|
作者：
Moore, Malcolm J. [1 ]
Au, Heather Jane
Parulekar, Wendy
机构：
[1] Univ Toronto, Princess Margaret Hosp, NCI,Div Med Oncol & Hematol, Canada Clin Trials Grp Gastrointestinal Dis Commi, Toronto, ON, Canada
[2] Queens Univ, NCI, Canada Clin Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 28期
关键词：
D O I：
10.1200/JCO.2007.13.1862
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4508 / 4508
页数：1
相关论文
共 50 条
  • [1] Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
    Miksad, Rebecca A.
    Schnipper, Lowell
    Goldstein, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4506 - 4507
  • [2] Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients
    Samelis, Georgios F.
    Ekmektzoglou, Konstantinos
    Tsiakou, Andriani
    Giannakaki, Styliani
    Konstadoulakis, Manoussos
    HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1776 - 1781
  • [3] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [4] Gemcitabine plus cisplatin in advanced pancreatic cancer - Reply
    Heinemann, Volker
    Boeck, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1142 - 1143
  • [5] Management of Advanced Pancreatic Cancer with Gemcitabine Plus Erlotinib: Efficacy and Safety Results in Clinical Practice
    Diaz Beveridge, Robert
    Alcolea, Vicent
    Aparicio, Jorge
    Segura, Angel
    Garcia, Jose
    Corbellas, Miguel
    Fonfria, Maria
    Gimenez, Alejandra
    Montalar, Joaquin
    JOURNAL OF THE PANCREAS, 2014, 15 (01): : 19 - 24
  • [6] Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer
    Kim, Eunji
    Kim, Kyubo
    Chie, Eui Kyu
    Oh, Do-Youn
    Kim, Yong Tae
    JOURNAL OF BUON, 2017, 22 (04): : 1046 - 1052
  • [7] Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?
    Helmut Oettle
    Andreas Hilbig
    Nature Clinical Practice Oncology, 2007, 4 : 686 - 687
  • [8] Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?
    Oettle, H.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (12): : 686 - 687
  • [9] Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
    Yang, Zu-Yao
    Yuan, Jin-Qiu
    Di, Meng-Yang
    Zheng, Da-Yong
    Chen, Jin-Zhang
    Ding, Hong
    Wu, Xin-Yin
    Huang, Ya-Fang
    Mao, Chen
    Tang, Jin-Ling
    PLOS ONE, 2013, 8 (03):
  • [10] JCO Flashback: A Comparison of Erlotinib Plus Gemcitabine vs Gemcitabine Alone in Treating Advanced Pancreatic Cancer (2007)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4713 - 4713
12345